Bio Works Technologies Ab Stock Total Debt
BIOWKS Stock | SEK 0.88 0.03 3.30% |
Bio Works Technologies AB fundamentals help investors to digest information that contributes to Bio Works' financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Works' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Works stock.
Bio |
Bio Works Technologies AB Company Total Debt Analysis
Bio Works' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition |
Based on the latest financial disclosure, Bio Works Technologies AB has a Total Debt of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The total debt for all Sweden stocks is 100.0% higher than that of the company.
Bio Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Works' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Works could also be used in its relative valuation, which is a method of valuing Bio Works by comparing valuation metrics of similar companies.Bio Works is currently under evaluation in total debt category among its peers.
Bio Fundamentals
Return On Equity | -0.66 | |||
Return On Asset | -0.35 | |||
Profit Margin | (1.31) % | |||
Operating Margin | (1.27) % | |||
Current Valuation | 635.01 M | |||
Shares Outstanding | 34.87 M | |||
Shares Owned By Insiders | 54.85 % | |||
Shares Owned By Institutions | 5.59 % | |||
Price To Book | 8.03 X | |||
Price To Sales | 19.71 X | |||
Revenue | 21.91 M | |||
Gross Profit | 53.01 M | |||
EBITDA | (8.6 M) | |||
Net Income | (12.94 M) | |||
Cash And Equivalents | 46.35 M | |||
Cash Per Share | 2.40 X | |||
Current Ratio | 9.14 X | |||
Book Value Per Share | 2.55 X | |||
Cash Flow From Operations | (13.37 M) | |||
Earnings Per Share | (0.41) X | |||
Target Price | 27.0 | |||
Number Of Employees | 36 | |||
Beta | 0.99 | |||
Market Capitalization | 718.4 M | |||
Total Asset | 120.86 M | |||
Net Asset | 120.86 M |
About Bio Works Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Works Technologies AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Works using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Works Technologies AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Bio Stock
Bio Works financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Works security.